Provider comparison

NexLife vs Noom Med: Tirzepatide

A side-by-side look at NexLife and Noom Med for tirzepatide, including the lowest priced plan we found for each, evidence status for that price, and what each does and does not disclose about its clinical and pharmacy model.

Pricing compared (Tirzepatide)

Side-by-side facts

Pricing caveats

• These figures are each provider's lowest advertised monthly-equivalent for tirzepatide in our dataset, not necessarily an all-in first-year total — membership fees, lab costs, and consultation fees can apply on top and are shown on each provider's full review page.
• Neither price above carries a “Verified by GLP Ranked” label. That status requires an archived capture and a named reviewer on file, which we do not yet have for either provider — see each provider's review page for the full evidence ledger.
• Pricing changes; check each provider's page directly before deciding, and treat "cheapest today" as time-bound.

Which fits which scenario

We are not declaring an overall winner here: NexLife's dispensing pharmacy is not actually named to us (States use of U.S.-licensed 503A compounding pharmacies; specific pharmacy not yet named to us), and Noom Med's is not publicly disclosed to us. Under our published rubric, a provider whose dispensing pharmacy is undisclosed cannot score above 70 of 100 points regardless of price — so price comparisons alone should not be the deciding factor for either option. Because no price on this page carries a verified-by-us label, treat this comparison as a starting point for your own verification, not a recommendation.